HOME　/　PEPTIDES　/　CJC-1295 NO DAC + IPAMORELIN
PEPTIDE RESEARCH TOPIC

CJC-1295 No DAC + Ipamorelin Research Peptide

Explore CJC-1295 No DAC with Ipamorelin, compound identity, growth hormone pathways, component evidence, and limitations of combination claims.

TOPIC OVERVIEW

About CJC-1295 No DAC + Ipamorelin

Identity and names

This name describes a combination of a non-DAC GHRH analogue and ipamorelin. The non-DAC material is commonly called modified GRF(1-29); it must not be equated with long-acting DAC CJC-1295.

Compound type

The components are different peptides. A blend ratio, salt form, and analytical identity require documentation rather than inference from the label.

Mechanism

The GHRH component and ipamorelin act through different growth hormone release pathways. Ipamorelin has been investigated as a growth hormone secretagogue.

Research focus and evidence

Foundational studies of individual components do not establish the effectiveness, pharmacokinetics, or safety of the marketed combination.

Regulatory status and limits

FDA has discussed characterization, immunogenicity, and safety-information concerns for CJC-1295 and ipamorelin preparations. Component evidence is not approval of a blend.

Topics covered
  • non-DAC versus DAC identity
  • GHRH and secretagogue pathways
  • combination evidence limitations
  • analytical documentation
Common names and related terms: CJC-1295 No DAC + Ipamorelin, Mod GRF 1-29 + Ipamorelin
RESEARCH SUMMARY

What Is CJC-1295 No DAC + Ipamorelin?

LAST VERIFIEDOctober 7, 2026

The original ipamorelin pharmacology study demonstrated growth hormone release in experimental systems through a GHRP-like receptor. It did not test the CJC-1295 No DAC and ipamorelin blend. Raun et al., original ipamorelin pharmacology

FDA identifies concerns relevant to compounded CJC-1295 and ipamorelin, including peptide characterization and gaps in safety evidence. These component assessments cannot be used to claim that a particular combination is clinically validated. FDA, bulk-substance safety information

EVIDENCE PROFILE

CJC-1295 No DAC + Ipamorelin Research Evidence

A concise view of registered clinical research, PubMed-indexed literature, evidence stage, and important limitations.

LAST VERIFIEDOctober 7, 2026
Registered records0
Active studies0
Completed studies0
PubMed records10
Compound typeThe components are different peptides. A blend ratio, salt form, and analytical identity require documentation rather than inference from the label.
AliasesCJC-1295 No DAC + Ipamorelin, Mod GRF 1-29 + Ipamorelin
Evidence stageFoundational studies of individual components do not establish the effectiveness, pharmacokinetics, or safety of the marketed combination.
U.S. regulatory contextFDA has discussed characterization, immunogenicity, and safety-information concerns for CJC-1295 and ipamorelin preparations. Component evidence is not approval of a blend.
CLINICAL REGISTRY

Selected registered research

No matching intervention record was found in ClinicalTrials.gov during this verification. This does not mean that no research exists.

INDEXED LITERATURE

Selected PubMed records

PMID 98498221998 Nov · European journal of endocrinology

Ipamorelin, the first selective growth hormone secretagogue.

PMID 414764242026 Jan · The American journal of sports medicine

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

PMID 414902002026 Jan 1 · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

How to interpret this profile

Registry and publication counts describe discoverable records, not proof of effectiveness or safety. Study design, compound identity, population, endpoints, and regulatory context must be reviewed individually.

Primary sources: ClinicalTrials.gov (defined search) · PubMed (defined query)Checked October 7, 2026. Counts include interventional registry records with an explicit matching intervention name or alias; broad search results, biomarker-only observations, and unrelated compounds are excluded. Active includes recruiting, not yet recruiting, active not recruiting, and enrolling by invitation. PubMed is the linked title/abstract query count, not a number of clinical trials or a measure of evidence quality. Literature query matches can discuss the individual ingredients; they do not establish efficacy of the named blend. Generic CJC-1295 or thymosin beta-4 trials are not treated as evidence for these specific formulations.

Displayed records are selected for relevance and recency; the page does not reproduce the complete source databases.

START HERE

Essential CJC-1295 No DAC + Ipamorelin guides

What Is CJC-1295 Ipamorelin No DAC? Simple GuideWhat is CJC-1295 ipamorelin no DAC? Learn how this peptide blend works, its reported benefits, typical research dosing, and key safety facts.CJC-1295 Without DAC 5mg + Ipamorelin 5mg: Research GuideCJC-1295 without DAC 5mg and ipamorelin 5mg is a two-vial research stack. See how it is reconstituted, dosed, and what to check before buying.CJC-1295 No DAC, Ipamorelin & Tesamorelin: Research GuideCJC-1295 no DAC, ipamorelin, and tesamorelin are three research peptides studied for growth hormone and IGF-1 effects. Compare mechanisms and safety notes.
CJC-1295 NO DAC + IPAMORELIN KNOWLEDGE ARTICLESPage 1 of 2
01
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin: DAC or No DAC?

CJC-1295 ipamorelin DAC or no DAC? Compare half-life, dosing frequency, and GH release patterns to see which version fits a research protocol.

↗
03
KNOWLEDGE ARTICLE

CJC-1295 Without DAC & Ipamorelin Dosage Guide

Typical cjc 1295 without dac ipamorelin dosage ranges, injection timing, blend ratios, and weekly totals for research use, plus important safety notes.

↗
08
KNOWLEDGE ARTICLE

Side Effects of CJC-1295 No DAC and Ipamorelin

Side effects of CJC-1295 No DAC and ipamorelin include injection-site reactions, headaches, flushing, and water retention. Learn what reports say.

↗
10
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin No DAC Reconstitution Guide

CJC-1295 ipamorelin no DAC reconstitution guide: learn how to mix with bacteriostatic water, calculate doses, and store peptides safely for research use.

↗
11
KNOWLEDGE ARTICLE

Ipamorelin CJC-1295 Without DAC Dosage Guide

Ipamorelin CJC-1295 without DAC dosage in research literature typically runs 100-300 mcg per peptide, 1-3 times daily. See timing, blends, and safety notes.

↗
13
KNOWLEDGE ARTICLE

CJC-1295 No DAC Ipamorelin 10mg Blend Dosage Guide

Learn about CJC-1295 no DAC ipamorelin 10mg blend dosage, typical protocols, and safety considerations. This research peptide is not FDA-approved for human use.

↗
14
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin: With DAC or Without DAC?

CJC-1295 ipamorelin with DAC or without? Compare half-life, dosing frequency, and stacking logic so you can choose the right research protocol.

↗
16
KNOWLEDGE ARTICLE

CJC-1295 Without DAC Ipamorelin Dosage Guide

Learn the typical CJC-1295 without DAC ipamorelin dosage used in research, including frequency, blend ratios, and safety notes for US researchers.

↗
20
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin With DAC vs Without DAC

The DAC version lasts about a week; the no-DAC version lasts minutes. Compare CJC-1295 ipamorelin with DAC vs without DAC on dosing, timing, and safety.

↗